Literature DB >> 26361262

Current Insights into the Pathogenesis of Graves' Ophthalmopathy.

R S Bahn1.   

Abstract

Environmental, genetic, and immune factors are at play in the development of the variable clinical manifestations of Graves' ophthalmopathy (GO). Among the environmental contributions, smoking is the risk factor most consistently linked to the development or worsening of the disease. The close temporal relationship between the diagnoses of Graves' hyperthyroidism and GO have long suggested that these 2 autoimmune conditions may share pathophysiologic features. The finding that the thyrotropin receptor (TSHR) is expressed in orbital fibroblasts, the target cells in GO, supported the notion of a common autoantigen. Both cellular and humeral immunity directed against TSHR expressed on orbital fibroblasts likely initiate the disease process. Activation of helper T cells recognizing TSHR peptides and ligation of TSHR by TRAb lead to the secretion of inflammatory cytokines and chemokines, and enhanced hyaluronic acid (HA) production and adipogenesis. The resulting connective tissue remodeling results in varying degrees extraocular muscle enlargement and orbital fat expansion. A subset of orbital fibroblasts express CD34, are bone-marrow derived, and circulate as fibrocytes that infiltrate connective tissues at sites of injury or inflammation. As these express high levels of TSHR and are capable of producing copious cytokines and chemokines, they may represent an orbital fibroblast population that plays a central role in GO development. In addition to TSHR, orbital fibroblasts from patients with GO express high levels of IGF-1R. Recent studies suggest that these receptors engage in cross-talk induced by TSHR ligation to synergistically enhance TSHR signaling, HA production, and the secretion of inflammatory mediators. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26361262     DOI: 10.1055/s-0035-1555762

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  58 in total

1.  Orbital and nasal meningoencephaloceles secondary to chronic hydrocephalus: A rare cause of bilateral proptosis.

Authors:  Zachary B Jenner; Nuruddin Husein; Roy Riascos; Yoshua Esquenazi
Journal:  Neuroradiol J       Date:  2018-06-08

2.  Performance of apparent diffusion coefficient of medial and lateral rectus muscles in Graves' orbitopathy.

Authors:  Ahmed Ak Abdel Razek; Mohamed El-Hadidy; Mohamed E Moawad; Nader El-Metwaly; Amr A El-Said
Journal:  Neuroradiol J       Date:  2017-04-05

3.  Relationship between serum cholesterol and Graves' orbitopathy (GO): a confirmatory study.

Authors:  G Lanzolla; E Sabini; M A Profilo; B Mazzi; A Sframeli; R Rocchi; F Menconi; M Leo; M Nardi; P Vitti; C Marcocci; M Marinò
Journal:  J Endocrinol Invest       Date:  2018-06-19       Impact factor: 4.256

4.  Safety of total thyroid ablation in patients with Graves' orbitopathy.

Authors:  M Moleti; G Sturniolo; F Vermiglio
Journal:  J Endocrinol Invest       Date:  2016-05-20       Impact factor: 4.256

5.  Selenium rescues orbital fibroblasts from cell death induced by hydrogen peroxide: another molecular basis for the effects of selenium in graves' orbitopathy.

Authors:  Giovanna Rotondo Dottore; Riccardo Chiarini; Maria De Gregorio; Marenza Leo; Giamberto Casini; Luca Cestari; Stefano Sellari-Franceschini; Marco Nardi; Paolo Vitti; Claudio Marcocci; Michele Marinò
Journal:  Endocrine       Date:  2017-01-17       Impact factor: 3.633

6.  Arrestin-β-1 Physically Scaffolds TSH and IGF1 Receptors to Enable Crosstalk.

Authors:  Christine C Krieger; Alisa Boutin; Daesong Jang; Sarah J Morgan; J Paul Banga; George J Kahaly; Joanna Klubo-Gwiezdzinska; Susanne Neumann; Marvin C Gershengorn
Journal:  Endocrinology       Date:  2019-06-01       Impact factor: 4.736

Review 7.  Controversies in the management of Graves' disease in children.

Authors:  S A Rivkees
Journal:  J Endocrinol Invest       Date:  2016-05-06       Impact factor: 4.256

8.  Modulating TSH Receptor Signaling for Therapeutic Benefit.

Authors:  Gerd Krause; Anja Eckstein; Ralf Schülein
Journal:  Eur Thyroid J       Date:  2020-11-23

9.  Action of three bioavailable antioxidants in orbital fibroblasts from patients with Graves' orbitopathy (GO): a new frontier for GO treatment?

Authors:  G Rotondo Dottore; I Ionni; F Menconi; G Casini; S Sellari-Franceschini; M Nardi; P Vitti; C Marcocci; M Marinò
Journal:  J Endocrinol Invest       Date:  2017-06-27       Impact factor: 4.256

10.  Use of low-dose radioiodine ablation for Graves' orbitopathy: results of a pilot, perspective study in a small series of patients.

Authors:  M Leo; E Sabini; I Ionni; A Sframeli; B Mazzi; F Menconi; E Molinaro; F Bianchi; F Brozzi; P Santini; R Elisei; M Nardi; P Vitti; C Marcocci; M Marinò
Journal:  J Endocrinol Invest       Date:  2017-08-30       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.